argenx acquires Forte Biosciences for $2.2 billion to gain FB102 antibody, an anti-CD122 treatment showing Phase 1b efficacy in...

WCG CenterWatch 2025 Report reveals where AI adoption stands in clinical research, showing implementation gaps between aspiration and execution.

92% of clinical trial organizations plan AI investment within two years, though only one-third currently use it meaningfully across...

LITMUS Imaging Study validates imaging and serum biomarkers for MASLD fibrosis—here's what it means for endpoint strategy in your...

CHMP recommends marketing authorization for obicetrapib in the EU, with Phase 3 trials showing up to 50% LDL-C reductions...

FDA approves LYTENAVA, the first ophthalmic bevacizumab formulation for wet AMD, ending two decades of off-label use in retina...

A multicenter RCT in Nature Medicine just validated AI-based IRD diagnosis—and exposed a gaping hole in how the FDA...

Laminar Pharma's LAM561 Phase 2b/3 trial in glioblastoma completes enrollment with topline overall survival data expected in Q2 2027.

Genmab and AbbVie clarify that epcoritamab Phase 3 trial missed primary endpoint for overall survival in transplant-ineligible DLBCL patients.

Atsena receives EMA orphan status for ATSN-101 and ATSN-201, with Phase 3 trials already underway for rare retinal diseases.